Translational research studies of erbB oncogenes: selection strategies for breast cancer treatment

Related Experiment Video

Updated: Oct 30, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

B H Brandt1, A Beckmann, F Gebhardt

  • 1Institut für Klinische Chemie und Laboratoriumsmedizin, Westf. Wilh.-Universität Münster, Germany. brandt@uni-muenster.de

Cancer Letters
|February 12, 1998
PubMed

Insights

Gene copy numbers for EGFR and c-erbB-2 impact breast cancer patient outcomes. Specific gene dosages and protein concentrations correlate with prognosis, identifying unfavorable subgroups for targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gene dosage sensitivity affects specific gene families, including those in signal transduction pathways.
  • Epidermal Growth Factor Receptor (EGFR) and c-erbB-2 are key tyrosine kinase receptors in cancer.

Purpose of the Study:

  • To determine the gene dosages of EGFR and c-erbB-2.
  • To correlate gene dosages with intratumoral protein concentrations of EGFR and p185c-erbB-2.
  • To analyze the relationship between these factors and clinical outcomes in breast cancer patients.

Main Methods:

  • Retrospective study design.
  • Determination of gene dosages for EGFR and c-erbB-2.
  • Measurement of intratumoral EGFR and p185c-erbB-2 protein concentrations.
  • Life-table analysis for prognostic subgroup identification.

Main Results:

  • Unfavorable prognostic subgroups identified by specific EGFR gene copy number ranges ( < 0.4 and > 1.6) combined with high intratumoral EGFR concentration (> 56 fmol/mg).
  • High intratumoral p185c-erbB-2 concentration (> 26 HNU/mg) indicated a poor prognosis.
  • Specific quotients of EGFR and c-erbB-2 gene copy numbers (< 0.15 and > 4.35) were associated with unfavorable outcomes.

Conclusions:

  • EGFR and c-erbB-2 gene dosages and protein levels are significant prognostic indicators in breast cancer.
  • Identifying these molecular subgroups can aid in risk stratification and treatment decisions.
  • Further research into targeted therapies based on these genetic and protein markers is warranted.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...